Oryzon Genomics (Oryzon)

Oncology Corporate Profile

HQ Location

Sant Ferran 74
Cornellà de Llobregat
Barcelona, Spain 08940

Company Description

Oryzon is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with ROCHE. Oryzon's LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one is anticipated to enter clinical trials in early 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets.

Website: https://www.oryzon.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ORY-1001LSD1 inhibitorVarious cancer typesI

View additional information on product candidates here »

Pipeline image

Source


https://www.oryzon.com

Recent News Headlines

There are no news items to display